Actym Therapeutics Reaching $59.5 Million Total Funding by Raising $25.5M in Series A
This significant funding extension positions Actym Therapeutics as a leading force in the field of cancer immunotherapy, emphasizing the company’s dedication to innovative research and development that could revolutionize the treatment landscape for solid tumors.